
    
      Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every
      28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 4
      months for up to 1 year.
    
  